Copyright
©The Author(s) 2022.
World J Hepatol. May 27, 2022; 14(5): 923-943
Published online May 27, 2022. doi: 10.4254/wjh.v14.i5.923
Published online May 27, 2022. doi: 10.4254/wjh.v14.i5.923
Table 2 Magnetic resonance contrast agent
| Category | Molecule | Structure | Ioniity | Relaxivity | Recommended dose (mmol/kg) | Excretion |
| ECAs | Gadoterate meglumine (Dotarem) | Macrocyclic | Ionic | Standard | 0.1 | Renal |
| ECAs | Gadobutrol (Gadavist) | Macrocyclic | Non-ionic | Standard | 0.1 | Renal |
| ECAs | Gadoteridol (Prohance) | Macrocyclic | Non-ionic | Standard | 0.1 | Renal |
| ECAs | Gadopentetate dimeglumine (Magnevist) | Linear | Ionic | Standard | 0.1 | Renal |
| ECAs | Gadoversetamide (OptiMark) | Linear | Non-ionic | Standard | 0.1 | Renal |
| ECAs | Gadodiamide (Omniscan) | Linear | Non-ionic | Standard | 0.1 | Renal |
| HBA | Gd-EOB-DTPA (Eovist/Primovist) | Linear | Ionic | High | 0.025 | 50% renal, 50% biliary |
| HBA | Gd-BOPTA (MultiHance) | Linear | Ionic | High | 0.1 | 5% biliary, 95% renal |
| BPA | Gadofosveset trisodium (Ablavar) | Linear | Ionic | High | 0.03 | Renal |
- Citation: Gatti M, Maino C, Tore D, Carisio A, Darvizeh F, Tricarico E, Inchingolo R, Ippolito D, Faletti R. Benign focal liver lesions: The role of magnetic resonance imaging. World J Hepatol 2022; 14(5): 923-943
- URL: https://www.wjgnet.com/1948-5182/full/v14/i5/923.htm
- DOI: https://dx.doi.org/10.4254/wjh.v14.i5.923